Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

RDNT vs AORT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RDNT
RadNet, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$4.45B
5Y Perf.+237.4%
AORT
Artivion, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.72B
5Y Perf.+55.7%

RDNT vs AORT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RDNT logoRDNT
AORT logoAORT
IndustryMedical - Diagnostics & ResearchMedical - Devices
Market Cap$4.45B$1.72B
Revenue (TTM)$2.04B$459M
Net Income (TTM)$47M$12M
Gross Margin11.2%63.8%
Operating Margin3.0%7.4%
Forward P/E91.8x98.7x
Total Debt$1.86B$292M
Cash & Equiv.$767M$65M

RDNT vs AORTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RDNT
AORT
StockMay 20May 26Return
RadNet, Inc. (RDNT)100337.4+237.4%
Artivion, Inc. (AORT)100155.7+55.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: RDNT vs AORT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AORT leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. RadNet, Inc. is the stronger pick specifically for valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
RDNT
RadNet, Inc.
The Long-Run Compounder

RDNT is the clearest fit if your priority is long-term compounding.

  • 9.5% 10Y total return vs AORT's 188.9%
  • Lower P/E (91.8x vs 98.7x)
Best for: long-term compounding
AORT
Artivion, Inc.
The Income Pick

AORT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 4 yrs, beta 0.63
  • Rev growth 13.6%, EPS growth 165.6%, 3Y rev CAGR 12.0%
  • Lower volatility, beta 0.63, Low D/E 65.2%, current ratio 2.99x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthAORT logoAORT13.6% revenue growth vs RDNT's 11.5%
ValueRDNT logoRDNTLower P/E (91.8x vs 98.7x)
Quality / MarginsAORT logoAORT2.5% margin vs RDNT's 2.3%
Stability / SafetyAORT logoAORTBeta 0.63 vs RDNT's 1.43, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)AORT logoAORT+24.7% vs RDNT's +4.6%
Efficiency (ROA)AORT logoAORT1.3% ROA vs RDNT's 1.3%, ROIC 3.2% vs 2.0%

RDNT vs AORT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RDNTRadNet, Inc.
FY 2025
Commercial Insurance1
58.8%$1.1B
Medicare1
24.8%$477M
Capitation Arrangements
6.5%$126M
Health Care, Other
3.4%$65M
Medicaid1
2.7%$52M
Workers' Compensation/Personal Injury1
2.3%$45M
Health Care, Management Service
1.4%$28M
AORTArtivion, Inc.
FY 2025
Aortic Stent Grafts
36.1%$159M
On X
23.1%$102M
Preservation Services
21.6%$96M
Surgical Sealants
17.4%$77M
Other Products
1.8%$8M

RDNT vs AORT — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLAORTLAGGINGRDNT

Income & Cash Flow (Last 12 Months)

AORT leads this category, winning 6 of 6 comparable metrics.

RDNT is the larger business by revenue, generating $2.0B annually — 4.4x AORT's $459M. Profitability is closely matched — net margins range from 2.5% (AORT) to 2.3% (RDNT).

MetricRDNT logoRDNTRadNet, Inc.AORT logoAORTArtivion, Inc.
RevenueTrailing 12 months$2.0B$459M
EBITDAEarnings before interest/tax$214M$51M
Net IncomeAfter-tax profit$47M$12M
Free Cash FlowCash after capex-$178M$13M
Gross MarginGross profit ÷ Revenue+11.2%+63.8%
Operating MarginEBIT ÷ Revenue+3.0%+7.4%
Net MarginNet income ÷ Revenue+2.3%+2.5%
FCF MarginFCF ÷ Revenue-8.7%+2.8%
Rev. Growth (YoY)Latest quarter vs prior year+14.8%+17.5%
EPS Growth (YoY)Latest quarter vs prior year-114.1%+3.5%
AORT leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

RDNT leads this category, winning 5 of 5 comparable metrics.

On an enterprise value basis, RDNT's 25.9x EV/EBITDA is more attractive than AORT's 39.5x.

MetricRDNT logoRDNTRadNet, Inc.AORT logoAORTArtivion, Inc.
Market CapShares × price$4.5B$1.7B
Enterprise ValueMkt cap + debt − cash$5.5B$1.9B
Trailing P/EPrice ÷ TTM EPS-230.00x168.52x
Forward P/EPrice ÷ next-FY EPS est.91.75x98.69x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple25.88x39.50x
Price / SalesMarket cap ÷ Revenue2.18x3.89x
Price / BookPrice ÷ Book value/share3.19x3.72x
Price / FCFMarket cap ÷ FCF52.01x
RDNT leads this category, winning 5 of 5 comparable metrics.

Profitability & Efficiency

AORT leads this category, winning 7 of 9 comparable metrics.

RDNT delivers a 3.8% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $3 for AORT. AORT carries lower financial leverage with a 0.65x debt-to-equity ratio, signaling a more conservative balance sheet compared to RDNT's 1.37x. On the Piotroski fundamental quality scale (0–9), AORT scores 6/9 vs RDNT's 5/9, reflecting solid financial health.

MetricRDNT logoRDNTRadNet, Inc.AORT logoAORTArtivion, Inc.
ROE (TTM)Return on equity+3.8%+2.7%
ROA (TTM)Return on assets+1.3%+1.3%
ROICReturn on invested capital+2.0%+3.2%
ROCEReturn on capital employed+2.1%+3.6%
Piotroski ScoreFundamental quality 0–956
Debt / EquityFinancial leverage1.37x0.65x
Net DebtTotal debt minus cash$1.1B$227M
Cash & Equiv.Liquid assets$767M$65M
Total DebtShort + long-term debt$1.9B$292M
Interest CoverageEBIT ÷ Interest expense1.46x1.28x
AORT leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — RDNT and AORT each lead in 3 of 6 comparable metrics.

A $10,000 investment in RDNT five years ago would be worth $24,710 today (with dividends reinvested), compared to $11,543 for AORT. Over the past 12 months, AORT leads with a +24.7% total return vs RDNT's +4.6%. The 3-year compound annual growth rate (CAGR) favors AORT at 34.3% vs RDNT's 26.0% — a key indicator of consistent wealth creation.

MetricRDNT logoRDNTRadNet, Inc.AORT logoAORTArtivion, Inc.
YTD ReturnYear-to-date-19.0%-20.4%
1-Year ReturnPast 12 months+4.6%+24.7%
3-Year ReturnCumulative with dividends+100.0%+142.2%
5-Year ReturnCumulative with dividends+147.1%+15.4%
10-Year ReturnCumulative with dividends+947.4%+188.9%
CAGR (3Y)Annualised 3-year return+26.0%+34.3%
Evenly matched — RDNT and AORT each lead in 3 of 6 comparable metrics.

Risk & Volatility

AORT leads this category, winning 2 of 2 comparable metrics.

AORT is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RDNT's 1.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AORT currently trades 73.3% from its 52-week high vs RDNT's 67.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRDNT logoRDNTRadNet, Inc.AORT logoAORTArtivion, Inc.
Beta (5Y)Sensitivity to S&P 5001.43x0.63x
52-Week HighHighest price in past year$85.84$48.25
52-Week LowLowest price in past year$50.76$26.84
% of 52W HighCurrent price vs 52-week peak+67.0%+73.3%
RSI (14)Momentum oscillator 0–10051.342.1
Avg Volume (50D)Average daily shares traded822K385K
AORT leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

AORT leads this category, winning 1 of 1 comparable metric.

Wall Street rates RDNT as "Buy" and AORT as "Buy". Consensus price targets imply 60.0% upside for RDNT (target: $92) vs 46.9% for AORT (target: $52).

MetricRDNT logoRDNTRadNet, Inc.AORT logoAORTArtivion, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$92.00$52.00
# AnalystsCovering analysts1112
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises04
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
AORT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

AORT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RDNT leads in 1 (Valuation Metrics). 1 tied.

Best OverallArtivion, Inc. (AORT)Leads 4 of 6 categories
Loading custom metrics...

RDNT vs AORT: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is RDNT or AORT a better buy right now?

For growth investors, Artivion, Inc.

(AORT) is the stronger pick with 13. 6% revenue growth year-over-year, versus 11. 5% for RadNet, Inc. (RDNT). Artivion, Inc. (AORT) offers the better valuation at 168. 5x trailing P/E (98. 7x forward), making it the more compelling value choice. Analysts rate RadNet, Inc. (RDNT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — RDNT or AORT?

On forward P/E, RadNet, Inc.

is actually cheaper at 91. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — RDNT or AORT?

Over the past 5 years, RadNet, Inc.

(RDNT) delivered a total return of +147. 1%, compared to +15. 4% for Artivion, Inc. (AORT). Over 10 years, the gap is even starker: RDNT returned +947. 4% versus AORT's +188. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — RDNT or AORT?

By beta (market sensitivity over 5 years), Artivion, Inc.

(AORT) is the lower-risk stock at 0. 63β versus RadNet, Inc. 's 1. 43β — meaning RDNT is approximately 126% more volatile than AORT relative to the S&P 500. On balance sheet safety, Artivion, Inc. (AORT) carries a lower debt/equity ratio of 65% versus 137% for RadNet, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — RDNT or AORT?

By revenue growth (latest reported year), Artivion, Inc.

(AORT) is pulling ahead at 13. 6% versus 11. 5% for RadNet, Inc. (RDNT). On earnings-per-share growth, the picture is similar: Artivion, Inc. grew EPS 165. 6% year-over-year, compared to -768. 4% for RadNet, Inc.. Over a 3-year CAGR, RDNT leads at 12. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — RDNT or AORT?

RadNet, Inc.

(RDNT) is the more profitable company, earning 2. 3% net margin versus 2. 2% for Artivion, Inc. — meaning it keeps 2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AORT leads at 6. 1% versus 3. 0% for RDNT. At the gross margin level — before operating expenses — AORT leads at 61. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is RDNT or AORT more undervalued right now?

On forward earnings alone, RadNet, Inc.

(RDNT) trades at 91. 8x forward P/E versus 98. 7x for Artivion, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RDNT: 60. 0% to $92. 00.

08

Which pays a better dividend — RDNT or AORT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is RDNT or AORT better for a retirement portfolio?

For long-horizon retirement investors, Artivion, Inc.

(AORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +188. 9% 10Y return). Both have compounded well over 10 years (AORT: +188. 9%, RDNT: +947. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between RDNT and AORT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

RDNT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
Run This Screen
Stocks Like

AORT

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Gross Margin > 38%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform RDNT and AORT on the metrics below

Revenue Growth>
%
(RDNT: 14.8% · AORT: 17.5%)
Net Margin>
%
(RDNT: 2.3% · AORT: 2.5%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.